Economic evaluation of SP142 IHC assay versus 22C3 IHC assay in patients with unresectable locally advanced or metastatic triple-negative breast cancer in the Brazilian private healthcare system.

R. Ho,Mariana Mioti Sebastião,Jp Carvalho,Tomás Neves,M. Nussbaum

Economic evaluation of SP142 IHC assay versus 22C3 IHC assay in patients with unresectable locally advanced or metastatic triple-negative breast cancer in the Brazilian private healthcare system.

2020

R. Ho
Mariana Mioti Sebastião
Jp Carvalho
Tomás Neves
M. Nussbaum

e13097Background: The IMpassion130 trial has demonstrated that atezolizumab plus nab-paclitaxel results in significant clinical benefits for patients with unresectable locally advanced or metastati...

Keywords:

Immunohistochemistry
Internal medicine
Oncology
Triple-negative breast cancer
Private healthcare
in patient
Pathology
locally advanced
Economic evaluation
Medicine
Atezolizumab
Physical therapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations